Stocks · Zydus vs Dr Reddy's
Zydus Lifesciences vs Dr Reddy's: which Indian pharma stock has the stronger platform in 2026?
Differentiated molecule pipeline with biologics versus a scaled global generics and API platform. A factual, signed comparison, informational and not a recommendation to buy or sell either stock.
The verdict
Zydus Lifesciences is a differentiated pharma franchise with a novel drug pipeline and a growing biologics presence, while Dr Reddy's is a more scaled global generics business with a strong North American generic drug portfolio and an integrated API backbone. As of 2026-06-18, the systematic read scores Zydus Lifesciences Limited 79 and Dr. Reddy's Laboratories Limited 57 on the BazaarBaazi Crack Score, an Edge Score of 72 out of 100 to Zydus Lifesciences Limited.
BazaarBaaziSource & method
The matchup, at a glanceZYDUSLIFE 79 · DRREDDY 57
The Edge Score is a BazaarBaazi number for this matchup: 50 plus the gap between the two Crack Scores, capped at 100. 50 is a dead heat; the further above 50, the more decisively the systematic read favours the leader.
The case for eachStructural, not a tip
What each stock has going for it, factually. The Crack Score is the live systematic read; the edges are durable structural points, not forecasts.
The case for
Zydus Lifesciences Limited
Crack Score
79 / 100Bullish
Structural edges
- Novel drug pipeline creates asymmetric upside that a pure generics franchise cannot offer; successful approvals would be structurally re-rating events.
- Biologics and biosimilar investment gives a second growth engine beyond the commodity generics path.
- India branded business is well-established in chronic therapy segments, providing a stable domestic earnings base.
The case for
Dr. Reddy's Laboratories Limited
Crack Score
57 / 100Mixed
Structural edges
- Larger global generics platform with deeper North America and Europe presence gives more base revenue predictability.
- Integrated API business is a natural hedge against supply chain risk and adds an additional revenue stream in the API supply market.
- More complex generic filings (peptides, injectables) offer differentiated US launches with longer pricing durability.
The live ratios, side by sideQ4 FY26 results · live spot
Valuation and quality ratios computed from each company's latest filed results times its live spot, the same engine as the fundamentals calculator. The price-derived ratios (P/E, P/B, yield) move with the market; the rest hold until the next results.
| Zydus Lifesciences Limited | Dr. Reddy's Laboratories Limited | |
|---|---|---|
| Return on equity | n/a | 11.4% |
| Net profit margin | n/a | 12.8% |
| EPS growth (YoY) | n/a | -24.3% |
| Debt to equity | n/a | 0.21 |
Stored from each company's filed results, as of 2026-06-17 and currency-checked; anything we could not verify is shown as n/a rather than guessed. Move the price and watch them react in the calculator.
The comparison, side by sideFactual
Sector, indicative market cap, the live Crack Score and stance, then the structural read on each business. The live valuation and quality ratios are in the table above; read any ratio against the sector and the company's own history.
| Zydus Lifesciences Limited | Dr. Reddy's Laboratories Limited | |
|---|---|---|
| Sector | Pharmaceuticals | Pharmaceuticals |
| Market capIndicative band, refreshed monthly. Read the live figure from the latest screen. | ~1.1 lakh cr | ~1.1 lakh cr |
| Crack Score | 79 / 100 | 57 / 100 |
| Systematic stance | Bullish | Mixed |
| What they do | An integrated pharma company spanning branded generics in India, generic formulations for exports, biosimilars and a novel molecule pipeline. The Zydus Cadila heritage gives it depth in domestic formulations. | An integrated pharmaceutical company with a large global generics business, strong North America and European exposure, a significant API business, and a branded India portfolio. |
| The moat | A novel drug pipeline (including Saroglitazar and Desidustat), an established domestic branded franchise, and a growing biosimilars business that is capital-intensive to replicate. | Scaled global generics infrastructure, deep FDA filing history, a portfolio of complex generics in regulated markets, and an integrated API business that supplies both internal and external customers. |
| Key driver 2026 to 2030 | Pipeline conversion from novel molecules to commercial launches, biosimilar approvals in regulated markets, and growth in the India chronic segment. | Complex generic launches in North America, biosimilar penetration in Europe and the US, PSAI (API) segment growth, and the prescription drug base in the India business. |
| Main risk | Clinical and regulatory risk on the novel molecule pipeline, US FDA inspection outcomes on its manufacturing facilities, and pricing pressure in generic export markets. | US pricing environment for established generics, FDA site observations, generic erosion on key launched molecules, and currency headwinds on export revenues. |
| Best suited to | The investor who wants branded-India depth plus an options-value component from the novel drug pipeline, in a mid-to-large pharma franchise. | The investor who prefers a more scaled global generics anchor with a track record of navigating US FDA cycles and a more predictable base business. |
Compute the live valuation and quality ratios for either stock, or read the full signed verdict on ZYDUSLIFE and DRREDDY.
FAQ4 reader questions · AEO-eligible
The Zydus vs Dr Reddy's call, distilled and schema-marked for AI Overview, Perplexity, and reader search.
What is Zydus Lifesciences formerly known as?
Zydus Lifesciences was formerly known as Cadila Healthcare before the group reorganised its listed entity structure. The Zydus Cadila brand name remains associated with the parent group.
Which is bigger, Zydus or Dr Reddy's?
Dr Reddy's has historically had a larger revenue base from its global generics business. The indicative market capitalisation for both is shown on this page; use the latest quarterly results and the fundamentals calculator to compare current scale and margins.
Do Indian pharma stocks benefit from a weak rupee?
Both companies earn a significant share of their revenues in US dollars and other foreign currencies. A weaker rupee generally provides a translation tailwind for export revenues, though it also raises import costs for some raw materials. The net impact depends on the specific hedging and cost structure of each company.
What is Saroglitazar?
Saroglitazar is a novel molecule developed and commercialised by Zydus Lifesciences for fatty liver disease (NASH) and diabetic dyslipidaemia. It is one of the few novel drugs to come out of an Indian pharma company and is an example of the differentiated pipeline value embedded in the Zydus franchise.
Other matchups
Hub
Compare stocks
All stock head-to-heads
Compare
TCS vs Infosys
Margin and scale versus the guidance-led growth read
Compare
HDFC Bank vs ICICI Bank
Post-merger liability franchise versus best-in-class return discipline
Compare
SBI vs HDFC Bank
Sovereign-backed scale and value versus private-sector return quality
Compare
Reliance vs Bharti Airtel
Diversified conglomerate optionality versus a focused premium-telecom compounder
Compare
HAL vs BEL
Platform-maker order book versus faster-converting defence electronics
Compare
Maruti vs Tata Motors
Mass-market distribution and margins versus JLR-led global cyclicality
Compare
ONGC vs Coal India
Oil-price-linked upstream versus a coal monopoly with a dividend floor
Compare
ICICI Bank vs PNB
Best-in-class private return profile versus a PSU asset-quality recovery
Compare
Sun Pharma vs Cipla
Specialty-led US scale versus a balanced India and respiratory franchise
Compare
Trent vs Titan
Fast-fashion retail expansion versus a jewellery-led consumer compounder
Compare
Bajaj Finance vs Bajaj Finserv
The pure-play lending compounder versus the diversified financial-services holding
Compare
Adani Enterprises vs Adani Ports
The incubator conglomerate versus the cash-generating ports infrastructure operator
Compare
Tata Steel vs JSW Steel
An integrated global steelmaker versus a domestic-led capacity grower
Compare
NTPC vs Power Grid
Generation capacity growth versus regulated transmission stability
Compare
SBI vs ICICI Bank
Sovereign-backed scale and value versus best-in-class private return discipline
Compare
HUL vs Nestle India
Broad home and personal-care breadth versus a focused packaged-foods franchise
Compare
HDFC Bank vs Kotak Bank
Post-merger liability scale versus a focused, capital-efficient compounder
Compare
Axis Bank vs ICICI Bank
A large-franchise turnaround versus best-in-class return and earnings quality
Compare
TCS vs Wipro
Margin and scale leadership versus a leaner, restructuring-led recovery
Compare
Infosys vs HCLTech
Guidance-led pure-services read versus a differentiated products-and-engineering mix
Compare
Sun Pharma vs Dr Reddy's
Specialty-led US scale versus a generics-and-CDMO-led global diversification
Compare
Nestle India vs Britannia
Focused multi-category brand power versus a biscuits-led margin compounder
Compare
ITC vs HUL
Conglomerate cash-and-value versus the broadest mass-market FMCG compounder
Compare
UltraTech Cement vs Grasim
The cement industry leader versus an Aditya Birla conglomerate with a cement holding and new businesses
Compare
SBI Life vs HDFC Life
Bancassurance scale through SBI versus a diversified product mix and balanced distribution
Compare
L&T vs Siemens India
A diversified domestic engineering conglomerate versus a focused industrial-technology franchise
Compare
Bajaj Auto vs Eicher Motors
Export-led volume scale and EV push versus the premium Royal Enfield franchise
Compare
DMart vs Trent
Everyday-value grocery scale versus a fast-fashion and format-expansion story
Compare
Asian Paints vs Pidilite
Decorative paint leadership versus a monopoly in construction adhesives
Compare
DLF vs Lodha
The oldest premium residential-and-commercial franchise versus the fastest-growing pan-India developer
Compare
Tata Power vs Adani Green
A diversified integrated power company versus a pure-play utility-scale renewables developer
Compare
TVS Motor vs Hero MotoCorp
A premium-and-premium-EV challenger versus the mass-market volume king
Compare
Shree Cement vs Ambuja Cements
The highest-margin, most efficient pure-play cement operator versus Adani-backed capacity scale
Compare
Cipla vs Zydus Lifesciences
A global respiratory and chronic-therapy generics leader versus an India-first FMCG-pharma blend with a biosimilar optionality
Compare
Tech Mahindra vs LTIMindtree
A telecom-anchored restructuring story versus a high-quality engineering-and-digital merger compounder
Compare
Tata Consumer vs Varun Beverages
A multi-category Tata group FMCG build-out versus the fastest-growing PepsiCo bottler franchise in the world
Compare
Adani Power vs NTPC
A private-sector capacity-growth story versus the sovereign-backed power PSU with a renewable pivot
Compare
Cholamandalam vs Shriram Finance
A diversifying vehicle and home-finance NBFC versus the dominant used-commercial-vehicle lender
Compare
Hindalco vs Vedanta
A globally integrated aluminium-and-copper compounder versus a diversified natural-resources conglomerate
Compare
Mahindra vs Hyundai India
The SUV-led domestic compounder with a farm and EV platform versus the premium Korean franchise in the Indian market
Compare
PFC vs REC Ltd
Broader power financing platform versus a focused utility lender
Compare
Bank of Baroda vs Canara Bank
Diversified PSU franchise with international presence versus a sharper domestic recovery
Compare
Wipro vs HCLTech
Turnaround execution potential versus a steadier IT services and products blend
Compare
Godrej Consumer Products vs Dabur
Personal care and home care momentum versus defensive staples and wellness breadth
Compare
IndusInd Bank vs Kotak Bank
Higher-beta recovery potential versus quality-first private banking franchise
Compare
BPCL vs GAIL India
Downstream petroleum and refining leverage versus gas transmission and utility infrastructure
Compare
Tata Steel vs JSPL
Integrated steel scale and global diversification versus a focused domestic metals execution story
Compare
Torrent Pharma vs Divi's Labs
Branded formulations franchise versus specialty API and custom manufacturing excellence
Compare
ABB India vs CG Power
Premium electrification and automation technology versus a capital goods recovery and execution story
Compare
Motherson vs Bosch India
Global multi-category auto-component scale versus premium engineering and technology in auto systems
Compare
Muthoot Finance vs Bajaj Finance
Specialist gold-backed lending versus a broad consumer and retail credit platform
Compare
Adani Energy Solutions vs Tata Power
Transmission and distribution network expansion versus an integrated utility and clean energy franchise
Compare
IRFC vs PFC
Single-borrower sovereign railway book versus a broad power-sector financing platform
Compare
Tata Capital vs Bajaj Finance
Diversified Tata-group NBFC versus India's most scaled retail lending franchise
Compare
Mazagon Dock vs HAL
Naval shipbuilding monopoly versus aerospace manufacturing and MRO scale
Compare
Hindustan Zinc vs Vedanta
Pure zinc, lead and silver play versus a diversified global natural resources conglomerate
Compare
Cummins vs Siemens India
Engine and power generation specialist versus a diversified industrial technology and energy platform
Compare
Reliance vs Bharti Airtel
Vertically integrated conglomerate with multiple bets versus a focused telecom platform scaling into Africa and digital services
Compare
Maruti vs Tata Motors
Dominant passenger car volume leader versus a dual-play of EV transition and JLR luxury recovery
Compare
Coal India vs ONGC
Domestic monopoly coal producer versus an integrated oil and gas company exposed to global energy prices
Compare
HDFC AMC vs Jio Financial Services
Established mutual fund franchise with deep distribution versus a blank-cheque fintech backed by India's largest conglomerate
Compare
PNB vs Union Bank
NPA recovery trajectory and loan book quality improvement post the bad debt cycle
Compare
BEL vs Solar Industries
Electronics and radar systems PSU versus the private explosives and defence ammunition specialist
Compare
TCS vs Infosys
Scale and margin consistency versus vertical depth and consulting-led positioning
Compare
SBI vs HDFC Bank
Government-backed franchise with unmatched reach versus private sector quality and returns consistency
Compare
ABB vs Siemens India
Power and automation focus with a divestment-lightened portfolio versus a more diversified industrial-digital technology mix
Compare
United Spirits vs Varun Beverages
Premium Indian Made Foreign Liquor franchise versus the largest PepsiCo franchise bottler
Compare
Apollo Hospitals vs Sun Pharma
Hospital infrastructure and healthcare services platform versus a diversified global pharmaceutical company
Compare
IOC vs BPCL
India's largest oil refiner-marketer versus the privatisation candidate with an international upstream portfolio
Compare
Wipro vs Tech Mahindra
Broad-based enterprise IT versus telecom-rooted technology services with a manufacturing and 5G pivot
Compare
HCL Tech vs LTIM
Scale, products revenue, and margin consistency versus integration execution and faster revenue growth potential
Compare
Bajaj Auto vs TVS Motor
Premium motorcycle brand and export franchise versus diversified two-wheeler portfolio with aggressive EV positioning
Compare
Hindalco vs Tata Steel
Aluminium's EV and green transition tailwinds via Novelis versus steel's domestic infrastructure cycle leverage
Compare
Bajaj Finance vs Cholamandalam
Consumer lending breadth and franchise premium versus vehicle and secured lending with faster-growing aspirations
Compare
NTPC vs Adani Green Energy
Diversified power generation with a growing renewable arm versus a pure-play renewable developer with the largest India pipeline